Mirtazapin +pharma (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin +pharma, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients. The medication works by modulating neurotransmitter activity to improve mood and functional outcomes.

GNH USA supplies Mirtazapin +pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our global distribution network ensures reliable access to high‑quality products across diverse markets, adhering to stringent regulatory standards.

Mirtazapine, a noradrenergic and specific serotonergic antidepressant, is used primarily in the management of depressive disorders.

Major depressive disorder: reduces depressive symptoms and improves overall functioning.

Mirtazapine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome)

When prescribing mirtazapine, clinicians should consider several safety measures. - Monitor weight: patients may experience increased appetite and weight gain. - Assess sedation: may cause daytime drowsiness, especially at treatment initiation. - Evaluate hepatic function: use with caution in liver impairment. - Review concomitant CNS depressants: risk of additive sedation. - Avoid abrupt discontinuation: may lead to withdrawal symptoms such as anxiety or insomnia. - Store at ambient temperature: keep in original container, protect from moisture and light.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis or serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): increased risk of serotonin syndrome. - CNS depressants (e.g., alcohol, benzodiazepines): enhanced sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine plasma levels. - CYP3A4 inducers (e.g., carbamazepine, rifampin): may reduce mirtazapine effectiveness. - Anticoagulants (e.g., warfarin): potential alteration of INR values.